Doxycycline hyclate delayed-release - Allergan

Drug Profile

Doxycycline hyclate delayed-release - Allergan

Alternative Names: Doryx; WC 2055; WC-2031

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Warner Chilcott
  • Developer Allergan
  • Class Antibacterials; Collagenases; Skin disorder therapies; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne vulgaris; Chlamydial infections

Most Recent Events

  • 23 May 2016 First Generic equivalent available in USA for Acne vulgaris
  • 09 Feb 2015 Doxycycline hyclate delayed-release to be divested to Mayne Pharma in USA
  • 01 Oct 2013 Warner Chilcott has been acquired and merged into Actavis Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top